Journal
NUCLEAR MEDICINE COMMUNICATIONS
Volume 42, Issue 5, Pages 482-489Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MNM.0000000000001361
Keywords
dosimetry; Ga-68-PSMA; metastatic prostate cancer; Tc-99m-PSMA
Ask authors/readers for more resources
This study compared the efficacy of 68Ga-PSMA PET/CT and 99mTc-PSMA whole-body and regional SPECT/CT for detecting prostate cancer metastases. 68Ga-PSMA PET/CT detected more lesions than 99mTc-PSMA imaging, with additional lesions detected on delayed imaging. Regional 99mTc-PSMA SPECT/CT provided comparable organ doses to 99mTc-PSMA imaging.
Objective The present study was performed for head-to-head comparison between 68Ga-prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) and 99mTc-PSMA whole-body and regional single-photon emission computed tomography (SPECT)/CT for the detection of prostate cancer metastases. Methods Ten patients with metastatic prostate cancer underwent 99mTc-PSMA whole-body scan after intravenous injection of 230-330 MBq 99mTc-PSMA. Anterior and posterior whole-body images were acquired at 10 min, 2, 4 and/or 5/6 h post-injection. Additional SPECT/CT images were acquired for the involved sites, where planar images did not clearly identify the metastatic sites. All patients also underwent whole-body 68Ga-PSMA PET/CT and the results between the two techniques were compared for the detection of the metastatic lesions. Dosimetry analysis of the 99mTc-PSMA studies was performed using the MIRD-OLINDA approach. Results 68Ga-PSMA PET/CT detected lesions in all 10 patients, whereas 99mTc-PSMA imaging detected lesions in 9/10 patients. 68Ga-PSMA PET/CT imaging identified a total of 112 PSMA avid metastatic lesions compared to 57 (51%) lesions on 99mTc-PSMA imaging. Eighteen out of 57 lesions were detected only on delayed 99mTc-PSMA imaging at 4 h and/or 6 h. The regional 99mTc-PSMA SPECT detected 51/83 (61.0%) lesions seen on 68Ga-PSMA PET/CT. The dosimetry results demonstrated that 99mTc-PSMA provided organs' radiation absorbed/effective doses comparable with 99mTc-PSMA imaging. Conclusion Whole-body 99mTc-PSMA combined with regional SPECT/CT could be a potential alternative to 68Ga-PSMA PET for the detection of the advanced stage metastatic prostate cancer and for response evaluation to PSMA-based targeted therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available